Associated Papers
Identification of an ERCC2 mutation associated mutational signature of nucleotide excision repair deficiency in targeted panel sequencing data.
Stojkova O et al.
Biorxiv : the Preprint Server for Biology, 2026
41757092 (PubMed )
Supplement: media-1.pdf
Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer.
Börcsök J et al.
The Journal of Clinical Investigation, 2025
40829180 (PubMed )
Supplement: jci-135-186688-s236.xlsx › Figure1CD
Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer.
Kamran SC et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
37870965 (PubMed )
Supplement: ccr-23-0792_supplementary_table_s4_suppst4.xlsx › ChemoTrialGenes
ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer.
Li Q et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2019
Genomic characterization of response to chemoradiation in urothelial bladder cancer.
Desai NB et al.
Cancer, 2016
Select a paper to view details